{"slug":"tesamorelin-postherpetic","title":"Tesamorelin for Postherpetic Neuralgia: Evidence Review","body":"## What's breaking down\n\nPostherpetic neuralgia (PHN) follows shingles (herpes zoster) reactivation of varicella-zoster virus. Nerve damage occurs in affected dermatomes. Axons degenerate. Myelin sheaths suffer. Distal tissues lose innervation. Muscle atrophy can follow if reinnervation lags. Chronic pain persists because repair pathways fail to restore normal signaling. This is degeneration outrunning repair at the peripheral nerve level.\n\n## Why Tesamorelin might help you\n\nTesamorelin stimulates growth hormone release via the GH axis. If your postherpetic issue includes failed axonal regeneration or muscle atrophy from denervation, this layer matters.\n\n1. GH and IGF-1 signaling support Schwann cell activity and axon growth in nerve injury models.\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n3. Reduced visceral fat is a separate documented effect but not directly tied to neural recovery here.\n\n## How these fit together\n\nSingle-compound focus. Tesamorelin maps to the GH axis / visceral fat layer. If your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n\n- **Tesamorelin** → GH axis / visceral fat\n\n## What the evidence actually shows\n\nNo human trials test tesamorelin specifically in postherpetic neuralgia (preclinical|mechanistic). One ongoing Phase 2 trial (NCT03150511) evaluates tesamorelin after peripheral nerve injury repair in humans; outcomes include axonal regeneration via MRI/EMG and functional recovery. Results remain unpublished as of 2026 (human|ongoing).\n\nAnimal studies show growth hormone improves sciatic nerve regeneration after transection in rats: increased axon and Schwann cell density, higher compound muscle action potential amplitude, and better treadmill performance (preclinical|animal).\n\nA 2016 review summarizes GH/IGF-1 effects on multiple tissues in peripheral nerve injury, including reduced muscle atrophy (preclinical|review).\n\nTesamorelin reduces visceral adipose tissue in HIV patients per prior FDA data, but this does not address nerve repair (human|separate indication).\n\n## What scientists say\n\nResearchers note GH-based therapies show multi-modal promise for peripheral nerve injuries through accelerated regeneration and atrophy limitation, distinct from single-pathway agents (mechanistic|review). They call for clinical translation but emphasize lack of approved indications for neuropathic pain syndromes like PHN.\n\n## What people say on Reddit\n\nScant discussion. One thread mentions thymosin peptides for potential nerve repair in PHN contexts; no direct tesamorelin reports (anecdotal|none).\n\n## What people say on X\n\nNo relevant posts identified linking tesamorelin to postherpetic neuralgia or shingles recovery (anecdotal|none).\n\n## What we do not know\n\nDirect efficacy in PHN remains untested in humans. Optimal timing post-shingles, interaction with standard analgesics, and long-term nerve-specific outcomes lack data. Translation from traumatic nerve injury models to viral neuropathy is speculative.\n\n## Safety and limits\n\nTesamorelin carries documented effects on glucose metabolism and injection-site reactions from approved use. No PHN-specific safety data exist. Evidence base is early-stage for nerve applications overall.","register":"source_ledger","tags":["peptide","matrix"],"category":null,"style":{},"claims":[{"id":"c1","text":"No human trials test tesamorelin specifically in postherpetic neuralgia.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes evidence gap for this exact condition."},{"id":"c2","text":"Ongoing Phase 2 trial NCT03150511 tests tesamorelin after peripheral nerve injury repair for axonal regeneration and functional recovery.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Closest human data point on nerve repair."},{"id":"c3","text":"GH treatment in rats after sciatic nerve transection increased axon/Schwann cell density and improved functional measures.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Supports regeneration mechanism in animal models."},{"id":"c4","text":"GH/IGF-1 therapies show multi-modal effects on nerve regeneration and muscle preservation in peripheral nerve injury reviews.","section":"What scientists say","tier":"mechanistic","source_ids":["s4"],"source_status":"sourced","why_material":"Explains proposed repair pathway."}],"sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries.","summary":"Ongoing trial focused on PNI, not PHN.","claim_ids":["c1"]},{"id":"s2","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The investigators hypothesize that treatment with tesamorelin will result in faster and more substantial recovery of motor and sensory function following surgical repair of injured peripheral nerves.","summary":"Details trial aims for nerve recovery.","claim_ids":["c2"]},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22334173/","title":"Growth hormone treatment enhances the functional recovery of sciatic nerves after transection and repair","quote":"GH-treated rats showed increased cellularity at the lesion site together with more abundant immunoreactive axons and Schwann cells.","summary":"Rat study on GH for nerve repair.","claim_ids":["c3"]},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/27192539/","title":"Therapeutic augmentation of the growth hormone axis to enhance peripheral nerve regeneration","quote":"GH-based therapies carry great promise for the treatment of peripheral nerve injuries, given the multi-modal mechanism of action not seen with other experimental therapies.","summary":"Review of GH mechanisms in nerve injury.","claim_ids":["c4"]}],"prov":{"model":"grok/grok-4.3","action":"write"}}